secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2024-06-17T23:59:59+00:00
Accession:  0001193125-24-162069
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara Biotherapeutics announces 1-for-25 reverse stock split to comply with Nasdaq listing requirement
--------------------------------------------------------------------------------

- Reverse stock split at 1-for-25 ratio effective June 20, 2024 at 12:01 a.m. ET; post-split trading starts same day.
- Outstanding shares reduced from ~122.6M to ~4.9M; fractional shares paid in cash.
- Split authorized by stockholders on June 10, 2024; board set final ratio same day.
- Purpose: regain compliance with Nasdaq $1.00 minimum bid price for continued listing.
- Pre-funded warrants adjusted from 32.15M pre-split to ~1.29M post-split, subject to fractional cash payments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312524162069/0001193125-24-162069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312524162069/d705331d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-162069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer